Revenue was $607 million, with constant currency operational growth of 4% excluding a $46 million increase in non-cash Italy Lotto license amortization, up from about 1% in the first half. Year-to-date adjusted EBITDA rose 5% to $861 million, andMarginexcluding amortization rose 50 basis points …
The application for deramiocel is in final review with a decision date of November 22, 2026, after the FDA extended its review to consider a major amendment of about 30,000 pages. The efficacy summary supports a refined indication for upper limbImpairmentin patients over age …
Third quarter revenue was $3.7 billion, up 168% from a year ago and above guidance. Backlog reached about $133 billion, up 138%. AdjustedOperating Marginwas 10%, up from 1% in the first quarter and 5% in the second.
Third quarter net sales were $1.6 billion, down 9% on both a reported and organic basis. Operating EBITDA was $222 million, down 17%, with aMarginof 14%, down 140 basis points. Price was the largest headwind at roughly $120 million, with about 90% of that …
The July 1 Apotex transaction brought $100 million at closing, with another $11 million due within 12 months for inventory and transition services. Net funding is estimated at about $108 million, with taxes under $1 million. Third quarter net income was $77.8 million including …
Revenue rose 13% to $20.7 million from $18.4 million, above estimates of about $20 million. Licensing revenue grew 35% to $11.7 million and made up 57% of revenue. More than $7 million came from cash licensing agreements, led by new AI licensing deals signed …
Revenue rose 21% from a year ago.Quantum Computingas a service subscription revenue was $2.2 million, up 56%, and professional services were $2.0 million, up 318%. Commercial enterprises were 52% of revenue.
Annual recurring revenue reached $197 million, up 30%, and full-year revenue grew about 24%, split roughly evenly between one-time and recurring sales. Operating expenses fell to 47% of revenue in the fourth quarter from 51%. GrossMargindipped in the quarter but remains in the low …
Adjusted EPS was $0.43 against the roughly $0.42 analysts expected. Total revenue grew 31% to $439.8 million, adjusted EBITDA rose 33% to $64 million, and core pawnGross Profitrose 27%. Merchandise margin expanded 130 basis points to 37%.
Operating profit more than tripled to $5.6 million, and adjusted EBITDA more than doubled to $7.6 million, a 10.2% margin.Net Incomefrom continuing operations was $3.4 million, or $0.57 per diluted share, versus $0.10 a year ago, and adjusted EPS was $0.60 versus $0.13.